Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

2.4K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.4K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

1.0K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.0K
Adrenergic Agonists: Direct-Acting Agents01:30

Adrenergic Agonists: Direct-Acting Agents

3.0K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
3.0K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

526
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
526
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

2.9K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
2.9K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

1.7K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Improving Airway Clearance for Children With Neurologic Impairment Hospitalized With Pneumonia.

Hospital pediatrics·2026
Same author

Phase Ib study of enzalutamide with venetoclax in patients with metastatic castration-resistant prostate cancer.

Cancer chemotherapy and pharmacology·2025
Same author

Effects of an intergenerational Kindermusik class on stress and affect in older adults with dementia and their caregivers: a pilot study using ecological momentary assessment.

Frontiers in aging·2025
Same author

Use of glucagon-like peptide-1 receptor agonists in people with history of acute pancreatitis: TriNetX analysis.

Diabetes & metabolism·2025
Same author

Evaluating the effectiveness of combined T4 and T3 therapy or desiccated thyroid versus T4 monotherapy in hypothyroidism: a systematic review and meta-analysis.

BMC endocrine disorders·2024
Same author

Glucose ingestion does not lower testosterone concentrations in men on testosterone therapy.

Journal of investigative medicine : the official publication of the American Federation for Clinical Research·2024
Same journal

Relationship Between hsCRP, Glycaemic Control and Response to Sotagliflozin in Type 1 Diabetes: A Post Hoc Analysis of the inTandem3 Trial.

Diabetes, obesity & metabolism·2026
Same journal

Early Weight Regain After GLP-1 Receptor Agonist Discontinuation: Mechanisms and Implications for Treatment De-Escalation Strategies.

Diabetes, obesity & metabolism·2026
Same journal

First-Line Dapagliflozin, Metformin, or Combination Therapy in Type 2 Diabetes: Vascular and Molecular Outcomes of a Randomised Controlled Trial.

Diabetes, obesity & metabolism·2026
Same journal

Trends in Prevalence of Diabetes, Pre-Diabetes, and Cardiometabolic Risk Factor Control Among U.S. Adults, 2013-2023.

Diabetes, obesity & metabolism·2026
Same journal

Metabolic Risk-Attributable Dementia Burden: A Life-Course and Cautious Attribution Perspective.

Diabetes, obesity & metabolism·2026
Same journal

A Highly Powered Large Outcomes Randomised Controlled Trial Will Usually, but Not Always, Have Balanced Groups at Baseline.

Diabetes, obesity & metabolism·2026
See all related articles

Related Experiment Video

Updated: Mar 11, 2026

Assessment of Vascular Tone Responsiveness using Isolated Mesenteric Arteries with a Focus on Modulation by Perivascular Adipose Tissues
08:41

Assessment of Vascular Tone Responsiveness using Isolated Mesenteric Arteries with a Focus on Modulation by Perivascular Adipose Tissues

Published on: June 3, 2019

10.4K

Exenatide induces an increase in vasodilatory and a decrease in vasoconstrictive mediators.

Ajay Chaudhuri1, Husam Ghanim1, Antoine Makdissi1

  • 1Division of Endocrinology, Diabetes and Metabolism, State University of New York at Buffalo, Buffalo, New York.

Diabetes, Obesity & Metabolism
|November 29, 2016
PubMed
Summary
This summary is machine-generated.

Exenatide treatment in type 2 diabetes increases vasodilators like atrial natriuretic peptide and suppresses the renin-angiotensin system. These effects may explain exenatide's vasodilatory properties.

Keywords:
blood pressureexenatidevasodilatation

More Related Videos

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
07:46

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000

Published on: October 15, 2010

44.6K
Evaluating Vascular Hyperpermeability-inducing Agents in the Skin with the Miles Assay
08:43

Evaluating Vascular Hyperpermeability-inducing Agents in the Skin with the Miles Assay

Published on: June 19, 2018

16.0K

Related Experiment Videos

Last Updated: Mar 11, 2026

Assessment of Vascular Tone Responsiveness using Isolated Mesenteric Arteries with a Focus on Modulation by Perivascular Adipose Tissues
08:41

Assessment of Vascular Tone Responsiveness using Isolated Mesenteric Arteries with a Focus on Modulation by Perivascular Adipose Tissues

Published on: June 3, 2019

10.4K
Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
07:46

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000

Published on: October 15, 2010

44.6K
Evaluating Vascular Hyperpermeability-inducing Agents in the Skin with the Miles Assay
08:43

Evaluating Vascular Hyperpermeability-inducing Agents in the Skin with the Miles Assay

Published on: June 19, 2018

16.0K

Area of Science:

  • Cardiovascular Pharmacology
  • Endocrinology
  • Metabolic Diseases

Background:

  • Glucagon-like peptide-1 (GLP-1) analogs, including exenatide, are used for type 2 diabetes.
  • GLP-1 analogs are known to have vasodilatory effects.
  • The precise mechanisms behind exenatide's vasodilatory actions require further elucidation.

Purpose of the Study:

  • To investigate the impact of exenatide on key vasoactive factors.
  • To determine if exenatide modulates the renin-angiotensin system and other vascular mediators.
  • To correlate observed changes with exenatide's known vasodilatory effects.

Main Methods:

  • Analysis of blood samples and mononuclear cells (MNCs) from a prior study.
  • Patients with type 2 diabetes received single-dose or 12-week exenatide or placebo.
  • Measurement of plasma concentrations and MNC expression of various vasoactive factors, including atrial natriuretic peptide, cGMP, angiotensinogen, renin, angiotensin II, TGF-β, and P311.

Main Results:

  • Exenatide significantly increased plasma atrial natriuretic peptide, cyclic guanyl monophosphate (cGMP), and cyclic adenyl monophosphate at 12 weeks.
  • Plasma cGMP and adenylate cyclase expression in MNCs increased after a single exenatide dose.
  • Exenatide reduced angiotensinogen levels at 2 hours and 12 weeks, and renin/angiotensin II after a single dose.
  • Transforming growth factor-β and P311 expression were suppressed by exenatide at 12 weeks.

Conclusions:

  • Exenatide treatment leads to increased levels of vasodilatory peptides and signaling molecules.
  • Exenatide effectively suppresses components of the renin-angiotensin system.
  • These combined effects on vasoactive factors likely contribute to the vasodilatory actions of exenatide in type 2 diabetes.